Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) - Drugs In Development, 2021

July 2021 | 187 pages | ID: N5F0AE92C0F2EN
Global Markets Direct

Abstracts

Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica - Drugs In Development, 2021, provides an overview of the Neuromyelitis Optica (Central Nervous System) pipeline landscape.

Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or damage to the brain, spinal cord or nerves. NMO is an autoimmune condition which means a person’s immune system (the body’s natural defense again infection) reacts abnormally and attacks tissues and organs in the body. In cases of NMO, the immune system attacks the myelin sheath. Symptoms include loss of vision, weakness, numbness and bladder/bowel problems.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neuromyelitis Optica - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuromyelitis Optica (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 3, 5, 14, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Neuromyelitis Optica (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Neuromyelitis Optica (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Neuromyelitis Optica (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Neuromyelitis Optica (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Neuromyelitis Optica (Devic’s Syndrome) - Overview
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Development
Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment
Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development
Neuromyelitis Optica (Devic’s Syndrome) - Drug Profiles
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects
Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products
Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Accendatech Co Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Accure Therapeutics SL, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Aeterna Zentaris Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Ahead Therapeutics SL, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Aprilbio Co Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Apsara Therapeutics, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bio-Thera Solutions Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Biogen Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Boston Pharmaceuticals Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chord Therapeutics Sarl, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Cour Pharmaceuticals Development Co Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Elixiron Immunotherapeutics Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Endece LLC, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by EnhanX Biopharm Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Eternity Bioscience Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Horizon Therapeutics Plc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by ImCyse SA, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by ImmunAbs Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Imstem Biotechnology Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by LFB SA, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Mitsubishi Tanabe Pharma Corp, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Nanjing Iaso Biotherapeutics Co Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by NovelMed Therapeutics Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Orion BioScience Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Rongchang Pharmaceuticals Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Samsung Bioepis Co Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Tasly Biopharmaceuticals Co Ltd, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Tolerion Inc, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, 2021
Neuromyelitis Optica (Devic’s Syndrome) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021